MCL1 and lip and oral cavity carcinoma: Our findings suggest that targeting the EGFR/mTOR/Mcl-1 axis with afatinib could be a promising therapeutic strategy for oral cancer treatment, particularly in patients with high EGFR and Mcl-1 co-expression.